Recruiting Breast Cancer Studies in Dallas
Study of AVZO-021 in Patients With Advanced Solid Tumors
This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients...
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The ma...
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients
This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with Olaparib or Niraparib....
Prediction of Neoadjuvant Chemotherapy Response Using Contrast-Enhanced Ultrasound in Patients With Locally Advanced Breast Cancer
This phase II/III trial studies if contrast-enhanced ultrasounds using a contrast dye, perflutren lipid microspheres (Definity), can predict the response to chemotherapy by estimating the pressure in ...
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNB...
LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer
The aim of this Phase 1b/2 study is to investigate the safety, efficacy, and pharmacokinetics (PK) of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (I...
Converting HR+ Breast Cancer Into an Individualized Vaccine
Newly diagnosed post-menopausal women with clinical stage II-III, HR+HER2- breast cancer are eligible to a randomized trial, concurrently open at five US academic institutions. Patients receiving 4 mo...
Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer
The purpose of this study is to determine the impact of pre-operative cryoablation, and immune checkpoint inhibition (ICI) on on 3-year Event Free Survival (EFS), in women with residual hormone recept...
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with non-Luminal A hormone recept...
Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
The aim of this study is to identify the optimal dose for Vosilasarm (EP0062) as monotherapy and in combination with standard-of-care therapies to assess its Safety, Tolerability, Pharmacokinetics, an...
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
The purpose of this study is to better understand how the immune system plays a role in fighting breast cancer and specifically research if the immune system response against breast cancer can be impr...
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals...
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
This phase II trial tests how well neratinib prior to the primary treatment (neoadjuvant) works in treating patients with stage I-III HER2 mutated lobular breast cancers. Neratinib is in a class of me...
About Breast Cancer Clinical Trials in Dallas
Breast cancer is a disease in which cells in the breast grow out of control. It is the most common cancer in women worldwide and can also occur in men. Treatment options include surgery, radiation, chemotherapy, hormone therapy, and targeted therapies.
There are currently 13 breast cancer clinical trials recruiting participants in Dallas, TEXAS. These studies are seeking a combined 1,892 participants. Research is being sponsored by Avenzo Therapeutics, Inc., Merck Sharp & Dohme LLC, Artios Pharma Ltd and 9 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Breast Cancer Clinical Trials in Dallas — FAQ
Are there breast cancer clinical trials in Dallas?
Yes, there are 13 breast cancer clinical trials currently recruiting in Dallas, TEXAS. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Dallas?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Dallas research site will contact you about next steps.
Are clinical trials in Dallas free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Dallas studies also compensate for your time and travel.
What breast cancer treatments are being tested?
The 13 active trials in Dallas are testing new therapies including novel drugs, biologics, and treatment approaches for breast cancer.
Data updated March 2, 2026 from ClinicalTrials.gov